Medtech ETF outflows top $500 million since August on Wegovy worries
Reuters
Published Nov 13, 2023 01:11PM ET
By Bansari Mayur Kamdar and Amruta Khandekar
(Reuters) - Investors are exiting exchange traded funds (ETFs) that track medical technology and device firms due to growing concerns over the impact new weight-loss drugs will have on their businesses.
So far this month net outflows from the iShares U.S. Medical Devices ETF have been $32.5 million, LSEG Lipper data showed.
Many investors are increasingly wary that the popularity of weight-loss drugs could hurt corners of the health care sector focused on treating issues related to excess weight, from makers of bariatric surgery devices to companies whose products address the issues such as diabetes and sleep apnea.
Stocks in the sector have tumbled since Aug. 8, when Novo Nordisk (NYSE:NVO) said its obesity drug Wegovy reduced the risk of major cardiovascular events by 20% in overweight or obese people with a history of heart disease.
The iShares fund, with assets of $4.6 billion, has seen outflows of nearly $371.4 million and fallen 16% since August.
The smaller SPDR S&P Health Care Equipment (NYSE:XHE) ETF, with net assets of $293 million, has seen outflows of $12 million so far this month. It has shed $183 million and dropped about 30% since August.
Some market participants say the selloff may be overdone.
"There could be a slight reduction in things like cardiovascular events over time, but it's not going to devastate the market," said Jeff Jonas, Portfolio Manager at Gabelli Funds.
"It's not worth a 10% hit to earnings or the stock price."
The iShares U.S. Medical Devices ETF was on track for its best daily showing since April on Monday, last up 2.5%, while the SPDR fund added 2.7% after data showed that Wegovy's heart protective benefits were more moderate than expected.
"We had some good cardiovascular data (for Wegovy) over the weekend, but we still don't know if patients are going to be taking these drugs for decades at a time and sustaining these benefits over many, many years," said Jonas.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.